CSL (ASX:CSL)
ASX announcement history & article coverage
Transparent by design.
Announcments by CSL (ASX:CSL) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
CSL enters exclusive agreement with Alentis Therapeutics
CSL pays US$355 million upfront to secure rare kidney and liver disease drug partnership
Update - Notification of buy-back - CSL
Update - Notification of buy-back - CSL
Update - Notification of buy-back - CSL
Update - Notification of buy-back - CSL
Update - Notification of buy-back - CSL
Notice of Meeting and Shareholder Pack 2026
Update - Notification of buy-back - CSL
Update - Notification of buy-back - CSL
Update - Dividend/Distribution - CSL
CSL confirms dividend currency conversions and 2 October payment date
Update - Notification of buy-back - CSL
Application for quotation of securities - CSL
Notification regarding unquoted securities - CSL
Notification of cessation of securities - CSL
Notification of cessation of securities - CSL
Application for quotation of securities - CSL
Change in substantial holding
Appendix 3Y - Alison Watkins AM
Appendix 3Y - Elaine Sorg
Appendix 3Y - Costa Saroukos
Appendix 3Y - Cameron Price
Appendix 3Y - Samantha Lewis
Appendix 3Y - Carolyn Hewson AO
Appendix 3Y - Brian Daniels
Appendix 3Y - Andrew Cuthbertson AO
Appendix 3Y - Brian McNamee AO
Notification regarding unquoted securities - CSL
Agreements with U.S. on Drug Prices and Manufacturing
Appendix 3Y - Alison Watkins AM
Appendix 3Y - Costa Saroukos
Appendix 3Y - Cameron Price
Appendix 3Y - Samantha Lewis
Appendix 3Y - Carolyn Hewson AO
Appendix 3Y - Andrew Cuthbertson AO
Appendix 3Y - Brian McNamee AO
Notification regarding unquoted securities - CSL
Notification of buy-back - CSL
CSL Appendix 4G and Corporate Governance Statement
CSL Results Presentation for FY2026
CSL reports FY26 revenue growth, large impairments, and outlines FY27 growth outlook with transformation progress
Dividend/Distribution - CSL
CSL Limited declares USD 1.62 unfranked dividend for H1 2026
CSL FY2026 Results
CSL reports FY26 net loss amid $7.1 billion impairments; targets 5% underlying NPAT growth in FY27
CSL Statutory Accounts for FY2026
CSL reports FY2026 revenue growth but statutory loss amid restructuring; commits to sustainability and executive pay reforms
Notification of cessation of securities - CSL
Notice of Investor/Analyst Briefing 2026 Full Year Result
CSL Limited to release 2026 full year results with investor briefing on 18 August
CSL Update on Enhanced Plasma Manufacturing
CSL to start clinical trials for enhanced plasma manufacturing process Horizon 2 in mid-2027
Notification of cessation of securities - CSL